Omega-3 fatty acid supplementation at 3.50-8.75 g/day to enterally fed patients with severe pneumonia for 7 days was relatively well-tolerated, shortened days of mechanical ventilation, and decreased hospital cost.
Key Findings
Results
Omega-3 FA supplementation significantly reduced mechanical ventilation duration in enterally fed patients with severe pneumonia.
Patients were randomly assigned to a control group or two experimental groups receiving 3.50g or 8.75g of omega-3 FA (EPA+DHA) daily for 7 days
Total sample size was 84 patients enrolled from January 2022 to June 2024
Reduction in MV duration was observed across both supplementation doses
Study was conducted in a medical intensive care unit setting with severe community-acquired pneumonia patients
Results
Omega-3 FA supplementation significantly reduced hospital expenses and daily hospital costs.
Both the 3.50g/day and 8.75g/day dosage groups showed reductions in hospital expenses compared to control
Daily hospital costs were also reduced in omega-3 supplemented groups
Cost outcomes were collected alongside clinical outcomes and tolerance parameters over the 7-day supplementation period
Results
The anticipated anti-inflammatory effect of omega-3 FA supplementation was not observed, but a trend of immune enhancement was noted.
Mechanistic analysis did not confirm the expected anti-inflammatory effects of omega-3 FA in this patient population
A trend toward immune enhancement was identified despite the absence of a significant anti-inflammatory signal
This finding was described as a mechanistic observation within the pilot study framework
Results
Both 3.50g/day and 8.75g/day doses of omega-3 FA were relatively well-tolerated in patients with severe pneumonia receiving enteral feeding.
Tolerance parameters were prospectively collected alongside clinical outcomes
Neither the lower (3.50g/day) nor higher (8.75g/day) dose produced clinically unacceptable tolerability issues
The study specifically aimed to identify both effective and clinically tolerable dosages as a primary objective
Supplementation duration was 7 days in all groups
Conclusions
This pilot study established that further investigation with larger sample sizes is warranted to confirm clinical benefits and establish optimal dosage.
The study was explicitly described as a pilot study with 84 total participants across three groups
Authors noted the need for 'adequate statistical power and larger sample size' to confirm findings
The dosage range of 3.50-8.75 g/day was identified as a candidate range for future investigation
The study period spanned January 2022 to June 2024
What This Means
This research suggests that giving omega-3 fatty acid supplements (specifically EPA and DHA, found in fish oil) through a feeding tube to critically ill patients with severe pneumonia may have meaningful clinical benefits. In this small pilot study of 84 intensive care unit patients, those who received either 3.50 grams or 8.75 grams of omega-3 fatty acids per day for one week spent fewer days on a mechanical ventilator and had lower hospital costs compared to patients who did not receive the supplement. Both doses appeared to be reasonably well-tolerated by patients.
Interestingly, the researchers expected to see reduced inflammation as the main mechanism behind any benefits — this is a well-known property of omega-3 fatty acids — but that effect was not clearly observed. Instead, they noticed a possible boost to patients' immune function, suggesting the mechanism of benefit may differ from what was originally hypothesized. This is an important observation that may guide future research into how omega-3 supplements work in critically ill patients.
Because this was a pilot study with a relatively small number of patients, the findings should be considered preliminary. The authors emphasize that larger, more rigorously powered studies are needed to confirm whether these benefits are real and to determine the best dose to use. Nevertheless, this research suggests that omega-3 supplementation in the range of 3.50 to 8.75 grams per day may be a safe and potentially beneficial addition to the nutritional care of severely ill pneumonia patients.
Check Your Own Numbers
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
You Q, Chen Y, Yu H, Zhang Y, Tang N, Rao Z. (2026). Exploring a tolerable and effective dosage of omega-3 fatty acids as a supplement in enterally fed patients with severe pneumonia: A pilot study.. Asia Pacific journal of clinical nutrition. https://doi.org/10.6133/apjcn.202606_35(3).0010